podcasts Ratings /ratings/en/research-insights/podcasts/2020-08-05-the-sp-pharma-dose-episode-35-regeneron-pharmaceuticals-steady-growth-vs-heavy-product-concentration content esgSubNav
In This List

The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

COMMENTS

Instant Insights: Key Takeaways From Our Research

COMMENTS

U.S. Oil And Gas: Oil Price Drops Could Bore Into Producer Spending

COMMENTS

Cracks In Consumer Confidence Amid Tariffs And Inflation Could Lead To Tighter U.S. Leisure Spending

COMMENTS

Pre-Tariff U.S. Middle-Market Collateralized Loan Obligation Rally Is Unlikely To Last

Listen: The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.